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a b s t r a c t
For unknown reasons, there is huge variability in risk conferred by different HPV types and, remarkably,
strong differences even between closely related variant lineages within each type. HPV16 is a uniquely
powerful carcinogenic type, causing approximately half of cervical cancer and most other HPV-related
cancers. To permit the large-scale study of HPV genome variability and precancer/cancer, starting with
HPV16 and cervical cancer, we developed a high-throughput next-generation sequencing (NGS) whole-
genome method. We designed a custom HPV16 AmpliSeq™ panel that generated 47 overlapping
amplicons covering 99% of the genome sequenced on the Ion Torrent Proton platform. After validating
with Sanger, the current “gold standard” of sequencing, in 89 specimens with concordance of 99.9%, we
used our NGS method and custom annotation pipeline to sequence 796 HPV16-positive exfoliated
cervical cell specimens. The median completion rate per sample was 98.0%.
Our method enabled us to discover novel SNPs, large contiguous deletions suggestive of viral
integration (OR of 27.3, 95% CI 3.3–222, P¼0.002), and the sensitive detection of variant lineage
coinfections. This method represents an innovative high-throughput, ultra-deep coverage technique for
HPV genomic sequencing, which, in turn, enables the investigation of the role of genetic variation in HPV
epidemiology and carcinogenesis.
Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The human papillomaviruses (HPVs) of the genus Alphapapillo-
mavirus are widely prevalent among human populations, infecting
anogenital and oral mucosal and cutaneous epithelia [1]. Although
most HPV infections are benign, speciﬁc types of HPV infections
have been estimated to cause approximately 610,000 cancers
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worldwide each year [2]. In fact, persistent infection with one of a
dozen carcinogenic HPV types is a well-established, necessary
cause of cervical cancer [3], the third leading cause of cancer in
women worldwide [4]. HPV also causes a large proportion of
vaginal, vulvar, penile, anal, and oropharyngeal cancers. Despite
the pervasiveness of “high-risk” HPV (HR-HPV) infections, only a
small fraction of women with a HR-HPV infection at any infected
site will progress to precancer or cancer [5,6]. This indicates that
additional risk factors are important for HR-HPV carcinogenesis,
potentially including viral genetic factors; however, these factors
remain poorly understood.
HPVs are small and evolve slowly, at nearly the same rate as the
human genome, since they use the host replication machinery. HPV’s
have a circular double-stranded DNA genome of approximately 8000
bases, encoding eight viral proteins on one strand using all three
coding frames [3]. The HPV genome consists of an early region (E1, 2,
4–7 genes), which codes for core viral functions, including the E6 and
E7 ORF, which are linked to cellular transformation. The late (L1-2
genes) region codes for the viral capsid proteins. A non-coding
upstream regulatory region (URR) contains DNA-protein binding
motifs and is involved in replication. Each unique HPV type is deﬁned
as differing from all other characterized HPV types by at least 10% in
the highly-conserved L1 nucleotide sequence [7]. We know that viral
genetic factors are important because, as mentioned above, HPV types
differ profoundly in carcinogenicity [8]. HPV type 16 (HPV16) is the
most important and potent carcinogenic HPV type, identiﬁed in
approximately 50% of cervical precancers and up to 60% of cervical
cancers [8,9], and the large majority of other HPV-induced
malignancies.
Cervical cancer is the most important and best understood site
of HPV carcinogenesis. In terms of absolute risk, persistent cervical
infection with HPV16 is among the most potent human carcino-
gens [10]. By contrast, genetically closely related HPV31 and
HPV35 are much less common and much less carcinogenic than
HPV16, each causing less than 5% of cervical cancers [8]. Therefore,
important genetic information linked to carcinogenic potential
must be embedded in the small HPV genome [11].
Strikingly, there is large variability in precancer/cancer (CIN3þ)
risk within HPV16 by variant lineage [12]. The nucleotide
sequences of HPV variant lineages differ from each other by 1%
to less than 10% across the entire genome [12]. HPV16 can be
classiﬁed into 4 main variant lineages related to human population
origins and movement. Although variants of HPV16 differ by only
approximately 200 nucleotides, the non-European HPV16 variant
lineages are associated with an increased risk, estimated up to 10-
fold, of invasive cancer compared to European variants [13–22].
Given the large differences in cancer risk associated with
limited deﬁnable genotypic variation, it should be possible to
determine speciﬁc SNPs or “viral haplotypes” (i.e., ﬁxed variations
across the viral genome) responsible for increased viral carcino-
genicity. The laboratory and analytic approach can be extended to
HPV16-related types, and eventually all HR-HPV types. However,
even with the relatively simple model of HPV16 genomic varia-
bility, in order to have statistical power to interrogate thoroughly
the genetic basis of HPV16 carcinogenicity, complete HPV genome
sequencing of many thousands of viruses from large population-
based studies of benign HPV16 infections and precancer/cancer are
needed [12]. The labor, time and budget to sequence these large-
scale HPV studies with current Sanger sequencing methods are
prohibitive. With the recent advent of next-generation sequencing
(NGS), determining the genetic basis for this variability is now
achievable.
Speciﬁcally, in response to the need for a high-throughput,
cost-effective, and robust HPV sequencing process, we have
developed a novel NGS assay, combining Ion AmpliSeq library
construction and Ion Torrent Sequencing technology [23]. Here,
we describe the novel method that permits the study of genetic
variability within HPV16 in relation to cervical cancer risk. We
whole-genome sequenced 796 HPV16-positive exfoliated cervical
cell specimens from the Kaiser Permanente Northern California
NCI HPV Persistence and Progression (PaP) cohort [24] and give
examples of novel insights enabled by this new method to the
study of HPV epidemiology.
2. Materials and methods
2.1. Study population
The HPV PaP cohort is a repository of residual cervical specimens
from approximately 55,000 women obtained during routine cervi-
cal cancer screening and testing at Kaiser Permanente Northern
California (KPNC). By design, the study focus is to determine risk
factors for precancer and cancer among HPV-positive women; thus,
45,000 of the specimens in PaP were selected because they were
HPV-positive at baseline. These baseline specimens were collected
in specimen transport medium (STM; Qiagen Inc., Gaithersburg,
MD, USA) between January 2007 and January 2011 [24].
In KPNC, women 30 and older were routinely screened every
3 years for cervical cancer by “cotesting”, i.e., by testing for a pool
of 13 carcinogenic HPV using the Hybrid Capture 2 (HC2; Qiagen)
test in addition to obtaining cervical cytology. Also, women aged
less than 30 with an equivocal Pap smear were triaged using the
HC2 test. Eligibility was deﬁned as specimens from women 21 and
older who had not opted out from having their specimen banked
and tested for HPV-related biomarkers including HPV genotypes.
De-identiﬁed data including age and follow-up cytologic and
pathologic results were obtained from electronic health records.
Our study included baseline exfoliated cervical cell specimens
from 796 HC2-positive women, previously found by a research-use-
only typing test to contain HPV16 DNA [25]: the study population
included 472 CIN3 precancer cases and 69 cancer cases, and 255
controls. The cases were diagnosed at enrollment; in addition, a few
original controls developed CIN3 during the 5-year study follow-up
period (n = 11) and were reclassiﬁed as cases. The controls were
deﬁned as baseline specimens with HPV16 DNA and no cytologic or
histologic evidence of even equivocal precancer (CIN2þ) during the
follow-up study period.
2.2. DNA isolation, HPV16 detection, and viral load estimation
HC2was conducted on STM specimens as part of routine cervical
cancer screening at KPNC enrollment per the manufacturer’s
instructions. DNA was extracted from the banked STM specimens
as previously described [26]. We have used a simple DNA isolation
technique: 100 ul of STM was incubated with a solution containing
Laureth12 and Proteinase K, and thereafter precipitated with an
ammonium acetate/ethanol precipitation solution and resuspended
in 100 ul of a TE solution. The MY09/M11 L1 degenerate primer PCR
(MY09/11 PCR) and type-speciﬁc dot-blot hybridization methods
were used at the Burk laboratory at Albert Einstein College of
Medicine, to identify the HPV16-containing HC2 positive STM
specimens [26,27]. Co-infections with other HPV types were
ignored. In addition to HPV typing, dot blot oligonucleotide hybri-
dization signal intensity, a measure of viral load, was evaluated by
two researchers using a qualitative index on a scale of 1–5
(weakest¼1 and strongest¼5). The index represents the strength
of the hybridization signal established by observing the density and
diameter of the PCR product on the autoradiogram. For the current
analyses, viral load was collapsed into dichotomous categories of
low (PCR signal strength index of 1–3) and high (PCR signal
strength index of 4–5) viral load [28].
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2.3. Ion AmpliSeq library preparation
A custom Ion AmpliSeq HPV16 panel was employed to amplify
the entire 7906 bp HPV16 genome as 47 overlapping amplicons
ranging in size from 181 bp to 375 bp. Our laboratory designed
custom HPV16 degenerate primers using a consensus sequence with
ambiguity codes (IUPAC) derived from seven sequences representing
major HPV16 lineages (2 European, 1 European/Asian, 1 African-1, 1
African-2 and 2 Asian-American) in order to design degenerate
primers for sequencing (Supplemental Table 1). HPV16 reference
sequences included: European.prototype, w0122|European.prototype,
w0724|European.asian, R872|African-1, R460|African-2, Qv00995|
Asian-American, Qv15321|Asian-American. Proprietary nucleotide
modiﬁcations were made to the degenerate primers which were
grouped into two overlapping primer pools.
Libraries were generated following the manufacturer’s Ion
AmpliSeq Library Preparation kit 2.0-96LV protocol (Life Technolo-
gies, Part #4480441) with modiﬁcations highlighted below. In brief,
1 ul of partially puriﬁed total DNA from exfoliated cervical cells
underwent two separate targeted 10 ul ampliﬁcation reactions
using Ion AmpliSeq HiFi Master Mix and each of two separate
non overlapping HPV16-speciﬁc primer pools for a total of two
ampliﬁcation reactions per sample. Thirty PCR cycles were per-
formed following the manufacturer’s cycle times and temperatures.
Amplicons from both primer pools were combined prior to FuPa
digestion and ligation to Ion Xpress Barcode Adapters (1–96)
enabling the pooling of 96 samples into one Proton sequencing
run. Our initial targeted ampliﬁcation was so robust that we opted
not to perform the optional second ampliﬁcation step using Ion
Torrent speciﬁc ampliﬁcation primers and therefore proceeded to
two rounds of Agencourt AMPure XP cleanup using a 0.5x followed
by 1.2x bead-to-sample volume ratio to remove input DNA and
unincorporated primers from the amplicons. Individual library
concentrations were determined using the Roche LightCycler 480
Instrument II (Part #05015278001) using the Kapa Biosystems
Library Quantiﬁication Kit—Ion Torrent/LightCycler 480 (Part
#KK4857). Based on qPCR results a total of 6 million templates
per sample were pooled. The ﬁnal pooled library concentration and
size distributionwas determined using the Agilent 2100 Bioanalyzer
(Agilent Technologies Part #G2940CA) with the Agilent BioAnalyzer
DNA High-Sensitivity LabChip (Agilent Technologies Part #5067-
4626). The pooled library averaged 305 bp in size (size range 266–
460 bp).
2.4. HPV16 complete genome sequencing: Ion torrent proton &
personal genome machine
Template emulsion PCR, emulsion breaking and enrichment were
performed using the Ion P1 Template OT2 200 Kit v3 (Part
#4488318) according to manufacturer’s instructions. In brief, an
input concentration of 0.016 to 0.3 library templates per Ion Sphere
Particle (ISP) was combined with emulsion PCR master mix and run
on the Ion One Touch 2 (Life Technologies Part #4474779). Enrich-
ment of template-positive ISPs by Dynabead MyOne Streptavidin C1
bead (Life Technologies, Part #65001) capture was conﬁrmed using
the EMD Millipore Guava easyCyte (EMD Millipore Part #0500-
5008). Sequencing a 96-well plate in its entirety on an Ion Torrent
318 chip (Life Technologies Part #4484355) was carried out using the
Ion PGM Sequencing 400 Kit (Life Technologies, Part #4482002)
following the manufacturer’s recommended protocols found on the
Ion Community Website (ioncommunity.lifetechnologies.com). Seq-
uencing on the Ion PGM Platform requires three sequencing runs to
achieve optimal read depth per sample. Sequencing a 96-well plate
in its entirety on an Ion P1 Chip Kit v2 (Life Technologies, Part
#4482321) was carried out using the Ion PI Sequencing 200 Kit v3.0
(Life Technologies, Part #44885315) following the manufacturer’s
recommended protocol (ioncommunity.lifetechnologies.com) and
required one sequencing run. Eight water controls and eight
HPV16-negative (but human DNA positive) controls were also
included (one per plate) to assess potential HPV16 contamination
and to determine if there was an inﬂuence of human DNA on the
speciﬁcity of sequencing.
2.5. HPV16 complete genome sequencing: Sanger
For a subset of the samples, the complete 8 kb genomes of
HPV16 isolates were ampliﬁed by overlapping PCR, as previously
described [29,30]. In brief, three sets of primers for nested PCR were
designed to amplify the entire genomes in 3 overlapping fragments
(Supplemental Table 2). For overlapping PCR, an equal mixture of
AmpliTaq Gold DNA polymerase (Applied Biosystems, Carlsbad, CA)
and Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA) was
utilized. PCR products of anticipated size, as determined by gel
analyses, were puriﬁed and directly sequenced on an ABI 3700
Sequencer in the Einstein Sequencing Facility. Comparison of repeat
sequencing of PCR products from the same isolates resulted in a
difference of less than one change per 8000 bp. Several additional
sequencing primers were used to obtain supplemental sequence to
clarify sequence ambiguity and assemble the complete genome.
The nucleotide sequences of HPV16 complete genomes were
aligned with each representative lineage and sublineage of HPV16
variants [22] using the program MAFFT v6.864b [31]. A maximum
likelihood (ML) tree was constructed using RAxML MPI v7.2.8.27
[32] with default parameters. SNPs within the HPV16 genomes
were determined from the global alignment using MEGA5 [33].
2.6. Next-generation sequence (NGS) alignment and quality metrics
Because the HPV genome is circular, one of the 47 amplicons was
split bioinformatically to create 48 overlapping contigs that were
mapped across the genome. Raw sequencing reads generated by the
Ion Torrent sequencer were quality and adaptor trimmed by Ion
Torrent Suite and then aligned to the HPV16R reference (7906 bp)
[34] sequence using TMAP. To ﬁlter out human reads, all the read
were realigned to hg19-HPV16 hybrid reference genome and only
HPV16 reads were kept. Resulting BAM ﬁles were merged according
to sample names and processed through an in-house quality control
(QC) and coverage analysis pipeline, which generated coverage
summary plots and per sample per amplicon read count heatmaps.
BAM ﬁles were then left aligned using the GATK LeftAlignIndels
module. Amplicon primers were trimmed from aligned reads.
2.7. HPV16 NGS variant calling and annotation database
The HPV16 genome was genotyped by GATK HaplotypeCaller
Version 3.3[35]. SNP and indel calls were made and ﬁltered by the
Torrent Variant Caller Version 4.2 (http://mendel.iontorrent.com/
ion-docs/Torrent-Variant-Caller-Plugin.html). For each sample, a
whole-genome sequence fasta ﬁle was generated by combining
results from TVC and GATK.
A customized HPV16 annotation database was built according
to the coordinates of each HPV gene and regulatory regions. All
identiﬁed HPV16 nucleotide variants were annotated with the
following features: HPV16 gene or region, amino acid changes, and
transcription factor binding site changes using the SnpEff program
[36]. CpG site changes were also annotated with a separate script.
2.8. Sequence completion and concordance rates
We evaluated several metrics to assess the quality and reliability
of our HPV16 NGS data: overall and per sample genome completion
rates, concordance among 18 replicated samples (replicated 1–5
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times across each plate, total replicates¼28), concordance with
Sanger sequencing data, overall HPV16 genome coverage and the
coverage distribution. Custom software was used to determine
completion rates across the HPV genome, concordance among
duplicate samples and concordance between Ion Torrent and Sanger
sequencing per sample and per locus. The sequence completion rate
was deﬁned as the percentage of the length of the genome sequence
and the total number of called positions across the genome,
calculated as the percent of the (total sequence positions called)/
(genome sequence length). Sequence concordance was deﬁned as
the percentage of matching bases at each position of the genome
when comparing methods or when comparing duplicates of the
same sample, and is used as a method of assessing the accuracy of
the assay. Concordance by sample was estimated as the percent of
the (total number of nucleotide positions that agree)/(total number
of called positions across the genome); and, concordance by position
was estimated as the percent of the (total number of sample pairs
that agree at a nucleotide position)/(total number of sample pairs
with sequence data at that position).
2.9. HPV16 variant lineages and co-infection detection
HPV16 variant lineage assignment was based on the maximum
likelihood (ML) tree topology constructed using RAxML MPI
v7.2.8.27 [32] including 16 HPV16 European and non-European
variant lineage reference sequences, and lineage assignments were
conﬁrmed with SNP patterns.
An in-house custom program was implemented to identify the
heterozygous calls using the VCF sequence ﬁles and diagnostic sites.
Diagnostic sites were HPV16 nucleotide positions that distinguished
HPV16 variant lineages (i.e., positions that were known to be variable
between the variant lineages). We built a hash table for the
diagnostic sites, and then mapped the diagnostic sites to the
associated position in each VCF ﬁle. The diagnostic sites that
contained more than one genotype call, the heterozygous sites, were
identiﬁed and compiled in a tab-delimited ﬁle with the sample ID,
position, depth, genotype and frequency of each identiﬁed variant.
Suspected co-infections were veriﬁed by manually inspecting
each woman’s individual sequence reads at each variable nucleo-
tide position to determine if there were more than one HPV16
isolate present. Regions with a high density of variants in close
proximity were inspected for the presence of shared SNPs unique
to a speciﬁc HPV16 variant lineage (e.g., a non-European variant
lineage) present in only a proportion of reads, and the other
proportion of reads with shared variants unique to a different
HPV16 variant lineage (e.g., a European variant lineage) in the
same woman. For example, a non-European lineage speciﬁc
nucleotide change should be present in the same shared reads
and a European lineage nucleotide change present in different
shared reads in the same woman (see Fig. 1). These lineage speciﬁc
changes were manually conﬁrmed across the genome.
2.10. Identiﬁcation of HPV16 novel SNPs
For comparative purposes we obtained 62 previously published
Sanger whole-genome HPV16 sequences [22]; previously unreported
SNPs were classiﬁed as “novel”. An in-house custom program was
developed to categorize these SNPs. The program used the SNP
information from the 62 published sequences [22] as the known SNP
baseline. These Sanger SNPs and a SNP list from Ion Torrent, after
applying QC to ﬁlter out low quality SNPs, were used to build the key
and value pair hash tables for both Ion Torrent and Sanger SNPs
respectively. The SNPs were then binned into three categories:
Ion Torrent only, Sanger only and the overlap between Sanger and
Ion Torrent.
Variable sites that were frequently heterozygous were manu-
ally inspected with Integrative Genomics Viewer (IGV; www.
broadinstitute.org/igv/) [37] and removed from the dataset if poor
quality. We only focused on variants that passed the QC ﬁlter.
2.11. Statistical analyses
The non-parametric Mann–Whitney U test was used to deter-
mine if HPV16 sequence coverage (expressed as the percentage of
amplicons exceeding 25 or 500 sequence coverage) was
signiﬁcantly different between the high and low viral load cate-
gories. Differences in the distribution of coverage in the high versus
low viral load categories were visualized by a violin plot and
conﬁrmed by Kolmogorov–Smirnov testing. A logistic regression
model was used to obtain the odds ratio (OR) and 95% conﬁdence
intervals (CI) for precancer and cancer using the controls as the
referent group. Statistical analyses were performed with SPSS
version 21.0 and R version 3.1.2; all statistical tests were two-sided.
3. Results
We whole-genome sequenced 796 HPV16-positive specimens
and report several metrics to demonstrate the high quality and
reliability of our assay and describe HPV16 genome variation based
on these NGS data.
3.1. HPV16 genome sequencing concordance and completion rates
Sequence concordance was very high among the 18 sample
duplicates ranging from 99.7 to 100% (mean 99.97%, standard devia-
tion [SD] 0.07). The median completion rate for 796 specimens was
98.0% (interquartile range 5.6%). To evaluate if the sequence comple-
tion rates were related to viral load, we compared the distribution of
samples with greater than 25 coverage in the low versus high viral
load categories. Viral load was estimated from the signal intensities
after dot blot oligonucleotide hybridization and were dichotomized by
the Burk laboratory into low (PCR signal strength index of 1–3) and
high (PCR signal strength index of 4–5) viral load categories. Sequence
completion rates were directly associated with viral load (i.e., samples
with a low viral load had fewer reads exceeding 25 coverage;
Mann–Whitney U test, Po0.0001). This relationship is illustrated
with a violin plot, which shows the greater variability in coverage for
the samples with a lower viral load (Kolmogorov–Smirnov Test;
Po0.0001) (Supplemental Fig. 1a). The same association held true
for samples with coverage exceeding 500 (Supplemental Fig. 1b).
To validate our approach, we determined the concordance
between Sanger, representing the current “gold standard” of
sequencing, and Ion Torrent sequence data in a random subset of
89 specimens. The mean concordance across the 7906 bp HPV16R
genome by sample was 99.97% (SD 0.13; range of 98.9 to 100%) and
by genomic position was 99.93% (SD 0.79; range of 55.6 to 100%;
Supplemental Fig. 2). There were only two nucleotide positions
where the concordance dropped below 85% (concordance of 66.7%
and 55.6%; Supplemental Fig. 2); these two outliers were located
within the E5 gene in a small region that was a challenge to amplify,
illustrated in Fig. 2a.
3.2. HPV16 genome coverage and quality
The sequence depth across the 48 overlapping amplicons is
illustrated for the 796 total specimens in Fig. 2. For 638 samples
(80.1% of samples), the average sequence depth per amplicon was
very high (5135 ), ranging from 134 to 213,829 coverage
(Fig. 2a, group I). Seventy percent of amplicons in this group I were
sequenced at depths exceeding 500 (Fig. 2b). Sequence depth per
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Fig. 1. HPV16 variant lineage co-infection identiﬁcation. Integrative Genomics Viewer (IGV) [37] screenshot showing an example of a European (EUR; A) lineage and non-
European (nonE; D3) lineage coinfection. Sequencing reads (forward reads in red and reverse in blue) show consistent variants across four nucleotide sites for both the
European and non-European variant lineages. Multiple sites across the HPV16 genome conﬁrm patterns seen in the smaller IGV window. The HPV16 reference nucleotide
position is shown ﬁrst for the variants highlighted in each callout, and the reference sequence is shown along the bottom of the window below the sequence reads. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. HPV16 sequence depth for 796 samples. (a) Heat map illustrates the sequence depth across 48 overlapping amplicons (columns 1–48) for 796 samples (rows 1–796)
displaying sequence depths 4100 (green cells), depths of 15 (white cells) and depths o2 (red cells). Asterisks highlight four poorly performing amplicons. High
quality sequence for 638 samples far exceeded 25 coverage (group I). Twenty-six samples contained large central deletions (group II). Fifty-ﬁve samples yielded high
quality and depth sequence data that contained some speciﬁc amplicon dropout (group III). Seventy-seven samples performed poorly (group IV). The HPV16 reference map
aligns each gene to the corresponding amplicon(s). The exaggerated overlap of adjacent HPV16 genes and regions (early genes: E6, E7, E1, E2, E4, E5; late genes: L2, L1; the
upstream regulatory region, URR; non-coding region, NC) in the map reﬂects the overlapping design of the amplicons. (b) Heat map of sequence depths 4500 (blue cells)
and less than 500 (white cells). (c) The number of samples (y-axis) that exceeded 50 (blue), 100 (red) and 200 (green) sequence coverage (x-axis) for one amplicon
(2% of genome) up to 48 amplicons (100% of the genome). (d) Summary statistics for the number of high quality group I plus group III samples (n¼693) that exceeded 80, 85,
90 and 95 percent sequence coverage at depths of greater than 25 , 50 , 100 , 200 and 500 . (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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amplicon for 55 samples was high, yet compromised in 24% of the
amplicons where coverage fell below 25 (Fig. 2a, group III).
Seventy-seven samples sequenced poorly across the entire genome
(Fig. 2a, group IV). There were four viral regions of low genomic
sequence complexity that were a challenge to amplify due to the
need for larger amplicons to bridge these regions corresponding to
amplicons 24, 26, 32 and 47 (asterisk, Fig. 2a), located within the
HPV16 E5, L2 and URR regions, that accounted for 379 bp or 4.8% of
the viral genome. Overall, Ion Torrent sequencing of 96 barcoded
samples on a Proton P1 sequencing chip generated high quality
sequence data at depths of 25 to over 500 that covered 80 to
100% of the viral genome in a single sequence run (Fig. 2c–d). The
water controls and HPV16-negative human DNA positive controls
were clear of HPV16 sequence reads with a median sequence depth
per amplicon of 1.1 .
3.3. Custom HPV annotation pipeline
We designed a custom pipeline for sequence variant calling and
annotation. This pipeline allowed us to identify sequence variants
and annotate them in a high-throughput manner. All SNPs were
annotated for HPV16 genomic position, missense/nonsense/silent
change to a coding gene, alteration of a presumed transcription
factor binding site (e.g., E2 binding sites [E2BS]), and CpG site
change (Table 1).
For example, our custom annotation pipeline allowed us to
automatically track alterations at CpG sites across the viral genome
relative to HPV16 variant lineage reference genomes. CpG
methylation of the HPV genome is highly associated with pre-
cancer as opposed to benign infection [38,39]; thus, it is con-
ceivable that part of the association of genomic variability and risk
of precancer could be mediated by CpG sites. The goal of this
analysis was to identify loss of known CpG sites, as well as identify
SNPs that created new CpG sites. In comparison to the HPV16
European prototype reference (NC_001526), the HPV16 European
variant lineages had the greatest number of known CpG site losses
and CpG site gains, particularly in the E2 gene region (Table 1).
CpG gains per sample ranged from 0 to 11 and losses ranged from
0 to 4 per sample.
We detected a total of 961 SNPs and 10 indels (insertions or
deletions) across the HPV16 genome (summarized in Table 1).
Regions with the greatest and least number of SNPs, given their
size (i.e., number of SNPs/region size in nucleotides), were L2 and
E7, respectively. There were 435 nonsynonymous changes; three
resulted in a premature stop (nonsense) within the E2 or E4 gene.
We replicated all singleton SNPs occurring in only one sample and
all indels for validation, and determined that 84.1% of these
singleton SNPs and indels validated. We identiﬁed 642 SNPs that
were not present in the Smith et al. [22] report of 62 HPV16 genome
sequences (termed “novel” SNPs). Fifty-two percent of these novel
SNPs led to coding changes. The percentages of non-synonymous
SNPs that were novel ranged from 63.2 to 83.3% for each of the
eight protein-coding genes.
3.4. HPV16 variant lineage risk associations
We determined HPV16 variant lineage assignment based on a
phylogenetic maximum likelihood tree for 719 women, excluding
the samples with poor read depth (Fig. 2a, group IV). 604 women
(84.0%) in our study of women living in Northern California had
an HPV16 European variant lineage (A) infection, including the
following sublineages: 493 A1, 80 A2, 4 A3, and 27 A4 (Asian).
There were 115 women (16.0%) with an HPV16 non-European
variant lineage infection: 17 B (African-1), 17 C (African-2), and
81 D (North American/Asian-American). We assessed HPV16
variant lineage associations with cervical precancer and cancer
compared to the most common European sublineage, A1
(Table 2). We conﬁrmed that women with an HPV16 non-
European lineage (B/C/D) infection had a signiﬁcantly increased
risk of cancer compared to women with an HPV16 European A1
lineage infection (OR of 4.3, 95% CI 2.1–8.5, P¼4.0105;
Table 2).
Table 1
Annotated HPV16 genome SNPs in independent specimens detected by NGS.
Gene/
feature
Size
(bp)
Total
SNPs
% Variable
sites
“Novel”
SNPsa
No.
indels
% Novel
SNPs
Silent Missense Start loss Nonsense % Novel
Nonsyn. SNPs
CpG site
lossb
CpG site
gainb
Total Novel Total Novel Total Novel Total Novel
E6 477 53 11.1 38 1 71.7 15 10 34 25 1 0 3 3 73.7% 0.3% 4.5%
E7 297 19 6.4 12 0 63.2 13 7 6 5 0 0 0 0 83.3% 0.2% 0.8%
E1 1949 168 8.6 112 1 66.7 96 57 72 55 0 0 1 1 76.7% 1.0% 22.4%
E2 1098 122 11.1 77 0 63.1 40 22 84 55 0 0 1 1 65.9% 13.6% 32.4%
E4 288 56 19.4 31 3 55.4 28 12 21 17 0 0 2 2 82.6% 8.5% 18.6%
E5 252 40 15.9 27 1 67.5 23 15 19 12 0 0 0 0 63.2% 0.0% 4.7%
L2 1422 253 17.8 171 1 67.6 115 66 141 105 0 0 1 1 74.6% 1.5% 9.1%
L1 1596 156 9.8 121 0 77.6 102 75 58 48 0 0 1 1 83.1% 0.5% 6.5%
URR 831 146 17.6 83 3 56.8 – – – – – – – – – 5.5% 2.5%
E2BSn 44 4 9.1 1 0 25.0 – – – – – – – – – – –
Nonsyn, nonsynonymous; freq, frequency; early genes: E6, E7, E1, E2, E4 (overlaps with the E2 gene region), E5; late genes: L2, L1; upstream regulatory region: URR.
Total number of variable positions, some SNPs had multiple variable alleles that led to multiple changes; † based on four E2 binding sites (E2BS) in the URR.
a SNPs were considered “novel” if they were not present in the 62 reference HPV16 Sanger sequences [22].
b Frequency of CpG site changes are shown for women with a HPV16 European variant lineage compared to the HPV16 European prototype reference sequence.
Table 2
HPV16 variant lineage risk associations.
Status Tested
variant
N Reference
variant
N OR 95% CI P
Control Non-EUR,
B/C/D
23 EUR, A1 145 1.0
CIN3 69 314 1.4 0.8–2.3 0.211
Cancer 23 34 4.3 2.1–8.5 4.0105
N, number of women in each lineage.
OR, odds ratio; 95% CI, 95% conﬁdence intervals.
CIN3, cervical intraepithelial neoplasia grade 3; CIN3þ , cervical intraepithelial
neoplasia grade 3 and cancer; EUR, European.
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3.5. Ion AmpliSeq can identify large deletions and HPV16 variant co-
infections
HPV16 whole-genome sequencing and Ion Torrent deep cover-
age enabled us to identify contiguous amplicons with very low or
no sequence reads, interpreted as genome deletions. Twenty-six
women contained large central deletions 777 to 4940 bp in size
(Fig. 2a, group II). Deleted regions were visualized in the Integra-
tive Genomics Viewer (IGV) [37] and identiﬁed based on an abrupt
drop in the sequence read depth from 4100 to approximately
zero. Complete coverage data for the 26 deletions and ﬂanking
sequences can be found in Supplemental Fig. 3. The deleted region
often included a fragment within the E2 gene, whereas the E6, E7
and URR regions generated high sequence read numbers (Fig. 3).
The samples with these deletions were strongly associated with
cancer (OR of 27.3, 95% CI 3.3–222, P¼0.002); occurring in 0.5% of
controls, 3.5% of cervical precancers and 13.5% of cancer cases.
The deep coverage, often surpassing 500 , enabled the iden-
tiﬁcation of frequent HPV16 variant lineage co-infections. Co-
infections were suspected in women with multiple ‘heterozygous’
allele calls (HPV is a monoploid genome). The co-infections were
conﬁrmed by the identiﬁcation and visualization of multiple
lineage-speciﬁc sequence variants occurring in shared sequence
reads, representing two separate HPV16 variant lineage molecules,
using IGV (see example in Fig. 1). The deep read depths allowed
estimation of the percent infection with each HPV16 variant
lineage with a threshold of 1% for the less abundant variant in
an HPV16 mixed infection.
4. Discussion
We developed and implemented a high-throughput, NGS tech-
nique based on Ampliseq and Ion Torrent technology to investigate
the nucleotide changes associated with human papillomavirus
oncogenicity. This report focused on the details of the new assay;
to demonstrate the importance of the development, we also
described selected applications of this technology to study HPV16
genomes in a large set of samples from the ﬁrst laboratory runs of a
large population-based study. To validate this approach we com-
pared the nucleotide sequence and coverage of a subset of samples
sequenced in parallel by overlapping PCR and Sanger sequencing of
PCR products, a gold standard of HPV genomics. Concordance of
nucleotide sequences across the genome was excellent, with
499.9% agreement. Overall, the genome sequences data quality
metrics for the 796 samples were very high; the concordance
among duplicates run on each plate exceeded 99%, and 86% of
samples had a 90% coverage of at least 25 with 96% of samples
having at least 80% coverage of 25 or greater.
We ﬁrst used our pipeline to categorize the HPV16 genomes into
well-established variant lineages [12] to test HPV16 sequence variation
and cervical cancer risk at the haplotype level. Dichotomizing the
HPV16 genomes to the deepest phylogenetic branching, A (European)
and B/C/D (non-European) variant lineages, we observed a higher risk
of precancer/cancer (CIN3þ) for the non-European variant lineages,
consistent with our and others previous results [see [12] for review].
This motivates a very large and detailed exploration of ﬁner HPV16
genetic variation among thousands of precancer/cancer cases and
controls from the KPNC cohort, which is now possible with our high-
throughput assay and is underway. A goal is to use the genetic data to
understand the mechanistic basis of speciﬁc genomic inﬂuences on
the natural history of HPV infections and cervical lesions.
Our large sequence-based data enabled us to make several novel
observations, previously unachievable with Sanger or targeted
sequencing, which deserve separate attention. With this dataset,
we are able to deﬁne a very large number of HPV16 lineages and
SNPs, suggesting that HPV16 actually represents hundreds of
distinct viruses. HPV researchers have tended to study HPV16 as a
categorical, speciﬁc entity. Instead, HPV16 should be thought of as a
group of very closely related, genetically-stable viruses, and epide-
miologic studies of HPV can now focus on a viral “isolate” level. For
example, it is conceivable that using NGS methods, viral transmis-
sion studies between sexual networks can be performed with
greater precision as to which partner transmitted a particular viral
isolate. Longitudinal natural history studies of HPV16 that have
observed gaps in HPV positivity (e.g., repeated detection following a
period of negative testing) have been performed mainly at the level
of individual genotypes. Instead, it will now be possible with greater
accuracy to determine whether re-appearing speciﬁc HPV16 genetic
isolates represents re-emergence from a poorly deﬁned latent state,
or acquisition of a new infection.
We were able to annotate numerous novel SNPs and CpG changes
across the HPV16 genome that may impact infection outcome.
HPV16 CpG site speciﬁc methylation has been suggested to be a
diagnostic biomarker of risk of cervical precancer/cancer among
HPV-positive women [38,40,41]. Methylation of CpG sites located in
the E2/E4, L2, L1 and URR gene regions have been associated with
infection outcome [see [42] for review], and we observed known CpG
site losses and CpG site gains in these regions, which should allow
further characterization of the biology of these sites and their
inﬂuence on the ﬁtness and pathogenicity of HPV16.
Another observation is the ﬁnding of co-infection with multiple,
different HPV16 isolates. Previous studies using smaller regions of
the HPV16 genome have estimated the frequency of cervical co-
infection with multiple HPV16 variant lineages to be low [43,44],
Fig. 3. Coverage depth by nucleotide position for three of the 26 HPV16 samples exhibiting large central deletions. Three samples with a large central deletion were
randomly chosen to illustrate the coverage depth pattern. The three sequence coverage plots (shown in blue, green and red) are over-laid upon the ORFs (early genes: E6, E7,
E1, E2/E4, E5; late genes: L2, L1) and the upstream regulatory region (URR) and corresponding nucleotide position of the HPV16 genome. (For interpretation of the references
to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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however our preliminary data (analyses underway) indicate that
this low rate may be due to the insensitivity of previous methods of
detection. Variant lineage determination has usually been done
with Sanger sequencing which is known to be relatively insensitive
to the detection of multiple sequences in one sample. NGS provides
hundreds of individuals sequence reads from each sample, whereas
Sanger sequencing provides a ‘consensus’ of the actual sequence.
Sanger sequencing can detect approximately 25% for a minority
sequence proportion, but with our new single molecule deep
sequencing we can estimate down to 1% co-infection proportions.
This is possible by noting consistent lineage speciﬁc changes in a
speciﬁc proportion of reads across the genome required for deﬁni-
tive calling of lower level infections. These data will allow the
examination of whether circulation of different HPV16 isolates is
independent, or whether they interact in some way, potentially
inﬂuencing the natural history of HPV16 infections. In microdissec-
tion studies of cervical pathology samples, the dogma has become
that different HPV types do not co-infect cervical cells [45,46],
although lesions produced by different types can abut each other. It
will now be possible to determine co-infections of different isolates
of HPV16 at the cellular level.
Also at the molecular level, the 26 large contiguous deletions
identiﬁed and highly associated with cancer are suggestive of a
pattern of HPV integration and expansion of a clonal lesion. HPV
DNA can integrate into the host genome, sometimes in precancer
(CIN3) and especially in cancers [47,48]. The deletion patterns
observed in our study documented decreased ampliﬁcation of
regions consistent with their loss, particularly in ORFs previously
shown to be disrupted in integration (i.e., E2, E4, E5 and regions of
E1 and L1), whereas the URR and viral oncogenes (E6 and E7)
remained intact. Twenty-ﬁve of 26 deletions lacked the E2 gene, a
ﬁnding consistent with a putative loss of E2-mediated repres-
sion of E6 and E7 expression or displacement of the viral
polyadenylation signal and dissociation of 30 signals in the
HPV16 early gene transcripts by splicing into cellular sequence
[49]. More work is needed to determine whether these deletions
are indeed signatures of HPV16 integration and lesions with a high
probability of progression.
5. Conclusions
We are in the process of extending our NGS method from
studies of HPV16 whole-genome sequence variation to DNA
derived from formalin-ﬁxed parafﬁn embedded (FFPE) tissues,
closely related types in alpha-9, and eventually all the cancer-
associated types, attempting to determine why HPV16 is a
uniquely powerful carcinogen. In summary, we have developed a
NGS method and sequence analysis pipeline that is adaptable to
high-throughput, enabling the practical sequencing of thousands
of HPV16-containing specimens from epidemiologically sound,
informative populations for the evaluation of the genetic basis of
HPV carcinogenicity. These NGS data have several advantages over
existing approaches and have already enabled the detection of a
large number of novel HPV16 SNPs, stable sublineage clades, CpG
site changes, large contiguous deletions suggestive of viral inte-
gration, and the sensitive detection of variant lineage coinfections.
It is not an exaggeration to state that NGS methods signal a new
era in the study of HPV and related cancers.
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